ANN ARBOR, Mich. (AP) _ Esperion Therapeutics Inc. (ESPR) on Wednesday reported first-quarter net income of $87.4 million, after reporting a loss in the same period a year earlier.
On a per-share basis, the Ann Arbor, Michigan-based company said it had net income of $3.07.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $1.32 per share.
The biopharmaceutical company posted revenue of $145.4 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $94.9 million.
Esperion Therapeutics shares have risen 5% since the beginning of the year. The stock has increased 18% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ESPR at https://www.zacks.com/ap/ESPR